Jasper Therapeutics reports positive briquilimab data: 3 SCD patients achieve 100% donor chimerism

Jasper Therapeutics, Inc.

First two sickle cell disease patients achieved 100% donor myeloid chimerism at Day 100; third at Day 30.
All three patients increased hemoglobin at last follow-up (to 11.4–14 g/dL from baseline 8–10 g/dL).
No graft-versus-host disease or briquilimab-related severe adverse events observed.
Data presented in plenary session at 2023 Tandem Meetings (ASTCT/CIBMTR) on novel antibody-based conditioning.
Study is Phase 1/2 (NCT05357482) evaluating briquilimab as conditioning for bone marrow transplant in SCD and beta thalassemia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.